The Chinese Patent Medicine Tongfengding Capsule for Gout in Adults: a Systematic Review of Safety and Effectiveness

Overview

Journal Adv Rheumatol

Publisher Biomed Central

Specialty Rheumatology

Date 2023 Jul 18

PMID 37464372

Authors

Qiaoli Hua

Xusheng Liu

Yang Luo

Yujie Lin

Kairong Zheng

Ai Xia

Qianchun Yang

Affiliations

Soon will be listed here.

Abstract

Background: Gout is a common inflammatory arthritis caused by increased serum uric acid levels. Untreated or insufficiently treated gout can lead to deposition of monosodium urate crystals in joints, cartilage, and kidneys. Although Tongfengding capsules, a Chinese patent medicine, have long been used to treat gout, their effects and safety have not been reviewed systematically. This study evaluated its efficacy and safety for gout in adults.

Methods: Randomized controlled trials involving Tongfengding capsule for gout in adults were searched from PubMed, EMBASE, Cochrane Central Register of Controlled Trials, CBM, CNKI, and VIP databases, and analyzed using the Cochrane Handbook criteria. The primary outcome measures were the total effective rate. The secondary outcome measures including the blood uric acid (BUA), 24-h urinary total protein (24-h UTP), blood urea nitrogen (BUN), interleukin (IL)-6, IL-8, tumor necrosis factor-alpha (TNF-α) and adverse effects. The risk of bias was evaluated in all included studies. RevMan ver. 5.3.5 and GRADE profiler was used for data analysis and assessing the quality of evidence, respectively.

Results: Six studies (n = 607 Chinese participants) were included. Tongfengding capsules plus conventional treatment significantly increased the total effective rate (RR 1.21, 95% CI 1.11-1.33), while reducing the BUA (MD - 66.05 µmol/L, 95% CI - 81.26 to - 50.84), 24-h UTP (MD - 0.83 g/24 h, 95% CI - 0.96 to - 0.70), BUN (MD - 0.90 mmol/L, 95% CI - 1.60 to - 0.20), IL-6 (MD - 6.99 ng/L, 95% CI - 13.22 to - 0.75), IL-8 (MD - 12.17 ng/L, 95% CI - 18.07 to - 6.27), TNF-α (MD - 8.50 ng/L, 95% CI - 15.50 to - 1.51), and adverse effects (RR 0.21, 95% CI 0.04-0.95).

Conclusion: Tongfengding capsules plus conventional treatment is safe and beneficial for adults with gout compared with conventional treatment.

References

Lee H, Yang G, Park Y, Kang H, Cho Y, Lee H . Epigallocatechin-3-Gallate Prevents Acute Gout by Suppressing NLRP3 Inflammasome Activation and Mitochondrial DNA Synthesis. Molecules. 2019; 24(11). PMC: 6600669. DOI: 10.3390/molecules24112138. View

Liu X, Liu K, Sun Q, Wang Y, Meng J, Xu Z . Efficacy and safety of febuxostat for treating hyperuricemia in patients with chronic kidney disease and in renal transplant recipients: A systematic review and meta-analysis. Exp Ther Med. 2018; 16(3):1859-1865. PMC: 6122173. DOI: 10.3892/etm.2018.6367. View

Zhou L, Liu X, Chen P, Liu L, Zhang Y, Wu Y . Systematic review and meta-analysis of the clinical efficacy and adverse effects of Chinese herbal decoction for the treatment of gout. PLoS One. 2014; 9(1):e85008. PMC: 3897404. DOI: 10.1371/journal.pone.0085008. View

Sinan Deveci O, Kabakci G, Okutucu S, Tulumen E, Aksoy H, Kaya E . The association between serum uric acid level and coronary artery disease. Int J Clin Pract. 2010; 64(7):900-7. DOI: 10.1111/j.1742-1241.2009.02263.x. View

Tsai C, Lin S, Kuo C, Huang C . Serum Uric Acid and Progression of Kidney Disease: A Longitudinal Analysis and Mini-Review. PLoS One. 2017; 12(1):e0170393. PMC: 5249245. DOI: 10.1371/journal.pone.0170393. View

Arromdee E, Michet C, Crowson C, OFallon W, Gabriel S . Epidemiology of gout: is the incidence rising?. J Rheumatol. 2002; 29(11):2403-6. View

Zhu Y, Pandya B, Choi H . Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011; 63(10):3136-41. DOI: 10.1002/art.30520. View

Chen-Xu M, Yokose C, Rai S, Pillinger M, Choi H . Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheumatol. 2019; 71(6):991-999. PMC: 6536335. DOI: 10.1002/art.40807. View

Kuo C, Grainge M, Mallen C, Zhang W, Doherty M . Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2014; 74(4):661-7. PMC: 4392307. DOI: 10.1136/annrheumdis-2013-204463. View

10.

Li X, Han M, Wang Y, Liu J . Chinese herbal medicine for gout: a systematic review of randomized clinical trials. Clin Rheumatol. 2013; 32(7):943-59. DOI: 10.1007/s10067-013-2274-7. View

11.

Wertheimer A, Morlock R, Becker M . A revised estimate of the burden of illness of gout. Curr Ther Res Clin Exp. 2014; 75:1-4. PMC: 3898191. DOI: 10.1016/j.curtheres.2013.04.003. View

12.

Perez-Ruiz F, Martinez-Indart L, Carmona L, Herrero-Beites A, Pijoan J, Krishnan E . Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2013; 73(1):177-82. DOI: 10.1136/annrheumdis-2012-202421. View

13.

Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P . EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006; 65(10):1312-24. PMC: 1798308. DOI: 10.1136/ard.2006.055269. View

14.

Graf S, Whittle S, Wechalekar M, Moi J, Barrett C, Hill C . Australian and New Zealand recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion in the 3e Initiative. Int J Rheum Dis. 2015; 18(3):341-51. DOI: 10.1111/1756-185X.12557. View

15.

Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J . 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2016; 76(1):29-42. DOI: 10.1136/annrheumdis-2016-209707. View

16.

Qaseem A, Harris R, Forciea M, Denberg T, Barry M, Boyd C . Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016; 166(1):58-68. DOI: 10.7326/M16-0570. View

17.

Hawkey C . Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology. 2000; 119(2):521-35. DOI: 10.1053/gast.2000.9561. View

18.

Neogi T . Clinical practice. Gout. N Engl J Med. 2011; 364(5):443-52. DOI: 10.1056/NEJMcp1001124. View

19.

Terkeltaub R . Clinical practice. Gout. N Engl J Med. 2003; 349(17):1647-55. DOI: 10.1056/NEJMcp030733. View

20.

Richette P, Bardin T . Gout. Lancet. 2009; 375(9711):318-28. DOI: 10.1016/S0140-6736(09)60883-7. View